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Aspiration  Pneumonitis  Caused  by  Delayed  Respiratory 
Depression  Following  Intrathecal  Morphine  Administration
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Opioid analgesia is the primary pharmacologic intervention for managing pain. However, opioids can cause 
various adverse effects including pruritus, nausea, constipation, and sedation. Respiratory depression is the most 
fatal side effect. Therefore, cautious monitoring of respiratory status must be done after opioid administration. 
Here, we report a patient who suffered from respiratory depression with deep sedation and aspiration 
pneumonitis after intrathecal morphine administration.  (Korean  J  Pain  2012;  25:  126-129)
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Implantable intrathecal morphine pumps have been in-
creasingly used in patients with intractable chronic pain 
[1,2]. Prior to making the decision to implant an ITMP, a 
trial administration of intrathecal morphine should be done 
to estimate the effective dose and to determine any unto-
ward side effects from the morphine. Side effects from in-
trathecal  morphine  administration  may  include  pruritus, 
nausea, vomiting, constipation, fluid retention, sexual dys-
function, urinary retention, and respiratory depression [3]. 
Respiratory depression is the most fatal side effect of in-
trathecal  morphine.  Therefore,  patients  receiving  intra-
thecal morphine should be monitored closely. Here, we re-
port a case of respiratory depression with deep sedation 
after trial administration of intrathecal morphine. 
CASE  REPORT
A 46-year-old man with chronic bilateral hip and leg 
pain was referred to our clinic. He was previously injured 
with a left sacral fracture and sacro-iliac joint separation 
from falling down in a building, and since then, he had 
been suffering from a tingling sensation and lancinating 
pain bilaterally in the hip and both legs. The intensity of 
the pain using the visual analogue scale (V AS) from 0 to 
10 mm was 8 mm. Initial neurologic examination of the pa-
t i e n t  s h o w e d  m o t o r  w e a k n e s s  o f  t h e  l o w e r  e x t r e m i t i e s  
(grade III/I) and moderate sensory weakness of the lower 
extremities.  His  electromyography  and  nerve  conduction 
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Fig. 1. Chest X-ray of the 
patient showing multifocal 
patchy consolidation consis-
tent with aspiration pneumo-
nitis (A) and the decreased 
extent of pulmonary opacifi-
cation in both central lung 
areas 3 days after initiation 
of the treatment (B). 
and right chronic L5-S1 radiculopathy. 
He  had  been  treated  with  acetaminophen/tramadol 
tablet 3 times a day, imipramine 25 mg 3 times a day, di-
valproate 500 mg twice a day, and pregabalin 75 mg twice 
a day orally. He had received a lumbar sympathetic gan-
glion block; however, his pain did not improve. Pethidine 
HCl 75 mg was administered intravenously 4 or 5 times a 
day. Despite the oral medications, his pain intensity was 
high (VAS 4-8 mm). 
He underwent a patient-controlled continuous epidural 
morphine  infusion since his pain was  responsive  to  in-
jections of opioids. Satisfactory catheter placement was 
confirmed by epidurogram and the reservoir bag contained 
p r e s e r v a t i v e  f r e e  m o r p h i n e  a t  a  c o n c e n t r a t i o n  o f  0 . 2 8  
mg/ml. The pump was programmed to deliver a basal rate 
of 0.5 ml/h, with an on-demand bolus dose of 4.0 ml, and 
a lock out interval of 30 minutes. He did not experience 
any  significant  adverse  events  and  reported  about  20% 
pain reduction. There was no further improvement in pain 
intensity despite increasing the basal rate up to 1.0 ml/h. 
In order to control his pain, we considered neuromodu-
lation. Spinal cord stimulation was expected to be difficult 
because of previous spinal surgery; therefore, implantation 
of an intrathecal morphine pump was selected after dis-
cussing it with the patient. Epidural PCA was stopped and 
he was placed in a lateral decubitus position on a table. 
His skin was prepared for needle insertion using an io-
dine-based antiseptic solution. A 25-gauge 10 cm spinal 
needle was inserted in the L4-5 interspinous space and 
ad v anced to obtain a spon taneous flow of cerebrospinal 
fluid (CSF). After confirming the CSF free flow through the 
needle, 0.3 mg of morphine sulfate (BC World, Korea) was 
administered  intrathecally.  The  dose  of  the  intrathecal 
m o r p h i n e  w a s  o n e  t e n t h  o f  t h e  e p i d u r a l l y  a d m i n i s t e r e d 
morphine in a half day.
One hour after morphine injection, he reported about 
60% pain reduction and his respiratory rate was 17/min. 
However, his pain recurred 8 hours after the morphine in-
jection with a VAS of 7. Tramadol 50 mg was injected be-
cause of severe pain 15 hours after intrathecal morphine 
injection. Epidural PCA was restarted. His family reported 
that he could communicate with others but he had dys-
arthria  and  drowsiness.  Twenty-one  hours  after  intra-
thecal morphine injection, he did not respond to painful 
stimulation. Epidural PCA was stopped.
Twenty-five hours after morphine injection, the pa-
tient was found to be unresponsive by his family members 
w i t h  a  r e s p i r a t o r y  r a t e  o f  1 5 / m i n ,  a  b l o o d  p r e s s u r e  o f 
88/54 mmHg, and pulse oximetry showing oxygen satu-
ration at about 69-71%. An oxygen mask with a reservoir 
bag was placed on him and he was transferred to the in-
tensive care unit. Naloxone 0.4 mg was administered in-
travenously, but his mental state did not improve. His chest 
radiograph revealed newly developed multifocal patchy con-
solidation in the left upper and lower lung zones (Fig. 1A). 
We assessed that he developed aspiration pneumonia due 
to  the  morphine-induced  deep  sedation.  Conservative 
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and ventilation care was done. Three days after the event, 
the blood gas was within normal range and was mentally 
alert so extubation was done. His chest radiograph also 
improved (Fig. 1B). He was discharged with his previous 
medication and his V AS score was 7. 
DISCUSSION
The side effects with opioid administration may include 
pruritus,  nausea,  vomiting,  constipation,  fluid  retention, 
sexual dysfunction, urinary retention, sedation and respi-
ratory depression [3]. Advanced sedation and respiratory 
depression is the most fatal side effect of opioid admini-
stration.  Opioid-related adverse  effects were  associated 
with significantly increased length of stays and hospital-
ization costs [4]. Sedation is a common adverse effect of 
opioids, particularly at the start and generally during the 
f i r s t  2 4  h o u r s  o f  o p i o i d  t h e r a p y  a n d  w i t h  i n c r e a s e s  i n 
o pi o i d d oses [5]. S ed a ti o n ge n er a ll y pr ec ed es sign ifi can t 
respiratory depression [6]. Opioid-induced sedation occurs 
on a continuum ranging from full consciousness to com-
plete  loss  of  consciousness  and  respiratory  arrest  [7]. 
Intrathecal opioid induced respiratory depression is divided 
into  2  types:  early  respiratory  depression  which  occurs 
within 2 hours of injection of the opioid and delayed respi-
ratory depression which occurs more than 2 hours after 
opioid administration [3]. Early respiratory depression due 
t o  i n t r a t h e c a l  m o r p h i n e  a d m i n i s t r a t i o n  h a s  n e v e r  b e e n  
reported. In contrast, all reports of clinically relevant de-
l a y e d  r e s p i r a t o r y  d e p r e s s i o n  h a v e  i n v o l v e d  t h e  a d m i n -
istration of morphine, either intrathecally or epidurally [8]. 
Delayed respiratory depression usually occurs 6-12 hours 
following intrathecal or epidural morphine administration 
[9]. This patient showed dysarthria which is a kind of opioid 
intoxication 15 hours after morphine injection, and after 
that, he looked sleepy. Approximately 15 to 21 hours after 
the morphine injection, he suffered from respiratory de-
pression with deep sedation. In this case, respiratory de-
pression associated with an opioid occurred relatively late. 
This patient was injected with tramadol after admin-
istration of the morphine since he still suffered from severe 
pain. Respiratory depression is not clinically significant in 
normal doses of tramadol; however, the concomitant ad-
ministration of intrathecal morphine and tramadol may in-
crease the risk of opioid-induced respiratory depression. 
The concomitant administration of neuraxial opioids and 
parenteral opioids, sedatives, hypnotics, or magnesium re-
quires increased monitoring (e.g., intensity, duration, or 
additional methods of monitoring) [10]. Careful monitoring 
was lacking in this case.
Unintended deep sedation from opioids is often a sign 
that the patient may be at higher risk for respiratory de-
pression [11], suggesting a need for increased frequency 
o f  a s s e s s m e n t  o f  t h e  s e d a t i o n  l e v e l s  a n d  r e s p i r a t o r y  
status. The patient exhibited a drowsy state for several 
hours after the morphine injection; however, the frequency 
for assessing the respiratory status did not increase. In 
addition, the respiratory rate was only monitored for the 
assessment of respiration. All patients receiving neuraxial 
opioids should be monitored for adequate ventilation (e.g., 
respiratory rate, depth of respiration), oxygenation (e.g., 
pulse oximetry when appropriate), and level of conscious-
ness [10].
Despite  the  opioid-induced  sedation  and  undetected 
respiratory depression, there are no universally accepted 
g u i d e l i n e s  t o  d i r e c t  e f f e c t i v e  a n d  s a f e  a s s e s s m e n t  a n d  
monitoring practices. As a result, there are considerable 
variations in monitoring practices. The American society 
of  anesthesiologist  recommended  practice  guidelines  for 
the management of respiratory depression associated with 
neuraxial opioid administration in 2009 [10]. The guideline 
emphasizes that the anesthesiologist should conduct a fo-
cused history and physical examination before administer-
ing neuraxial opioids. Particular attention should be di-
rected toward signs, symptoms, or a history of sleep ap-
nea, coexisting diseases or conditions (e.g., diabetes, obe-
sity), current medications (including preoperative opioids), 
and adverse effects after opioid administration. The guide-
line also recommends that monitoring should be performed 
a t l eas t o n ce per h o ur f o r th e firs t 12  h after a dm in-
istration, followed by monitoring at least once every 2 h 
for the next 12 h and after 24 h, frequency of monitoring 
should be dictated by the patient’s overall clinical condition 
and concurrent medications. Supplemental oxygen should 
b e  a d m i n i s t e r e d  t o  p a t i e n t s  w i t h  a l t e r e d  l e v e l s  o f  c o n-
sciousness, respiratory depression, or hypoxemia and con-
tinued until the patient is alert and no respiratory depres-
sion or hypoxemia is present.
In conclusion, respiratory depression with deep seda-
tion is a rare but fatal complication of opioid administ-
ration. Therefore, the clinician should watch out for this 
complication and assess respiratory status carefully.BY Whang, et al /  Intrathecal Morphine and Aspiration Pneumonitis 129
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